Mode
Text Size
Log in / Sign up

Neurology

728 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of emulated trial finds levetiracetam continuation associated with lower 90-day mortality after stroke
Neurology
Review of emulated trial finds levetiracetam continuation associated with lower 90-day mortality after stroke Taking This Common Stroke Medicine Might Save Lives After Discharge
This review summarizes an emulated target trial using Medicare claims (2008-2021) comparing continued versus discontinued outpatient levetir…
Older adults who kept taking a common seizure medication after a stroke had a lower risk of dying within three months.
FDA Approves DATSCAN (ioflupane I-123) for Striatal Dopamine Transporter Visualization in Suspected Parkinsonian Syndromes or Dementia with Lewy Bodies
Neurology FDA Approval
FDA Approves DATSCAN (ioflupane I-123) for Striatal Dopamine Transporter Visualization in Suspected Parkinsonian Syndromes or Dementia with Lewy Bodies FDA approves new brain imaging drug to help doctors diagnose Parkinson's and similar conditions
DATSCAN is approved as an adjunct diagnostic for striatal dopamine transporter visualization using SPECT brain imaging in adult patients wit…
FDA approves new brain imaging drug to help doctors diagnose Parkinson's and similar conditions.
FDA Approves Wainua (autoinjector) for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Neurology FDA Approval
FDA Approves Wainua (autoinjector) for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults FDA approves new monthly injection called Wainua for a rare nerve disease in adults
The FDA approved Wainua, a transthyretin-directed antisense oligonucleotide, for treating polyneuropathy of hereditary transthyretin-mediate…
FDA approves new monthly injection Wainua to treat nerve damage in adults with a rare inherited disease called hereditary transthyretin-medi…
Systematic review and meta-analysis of oxidative stress biomarkers in older adults with T2DM or Parkinson's disease
Neurology Meta-analysis
Systematic review and meta-analysis of oxidative stress biomarkers in older adults with T2DM or Parkinson's disease Parkinson’s and Diabetes Linked by Hidden Body Damage
This systematic review and meta-analysis evaluated oxidative stress biomarkers in serum, plasma, or leukocytes from 7,521 human subjects age…
Two common diseases may fuel each other through invisible cell damage, making care harder for millions living with both Parkinson's and type…
Observational review of phenoconversion rates and biomarker alignment in Parkinson's disease genetic cohorts
Neurology
Observational review of phenoconversion rates and biomarker alignment in Parkinson's disease genetic cohorts Do your symptoms match the biology, or is the disease hiding in plain sight?
This observational cohort analysis reviews phenoconversion rates and biomarker alignment in Parkinson's Progression Markers Initiative parti…
In people at genetic risk for Parkinson's, symptoms and biological markers often don't align, with nearly one-third showing advanced brain c…
Technical evaluation of sEEGnal automated EEG preprocessing pipeline versus expert-driven manual methods
Neurology
Technical evaluation of sEEGnal automated EEG preprocessing pipeline versus expert-driven manual methods New Software Matches Expert Quality for Brain Wave Analysis
This methodological development evaluates the sEEGnal automated EEG preprocessing pipeline against expert-driven manual preprocessing.
New automated software cleans messy brain wave data as accurately as human experts, helping doctors trust their diagnostic results faster.
Meta-analysis models cost-effectiveness of IV alteplase plus thrombectomy for large vessel occlusion stroke
Neurology Meta-analysis
Meta-analysis models cost-effectiveness of IV alteplase plus thrombectomy for large vessel occlusion stroke Adding alteplase to stroke surgery is cost-effective when treatment starts within 170 minutes
This meta-analysis models cost-effectiveness using individual patient data from 6 trials involving 2,268 patients across 16 countries.
Adding clot-busting medicine to stroke surgery saves money and improves value when treatment starts within 170 minutes, but benefits fade af…
Upadacitinib shows 94.1% remission at 26 weeks in Crohn's disease cohort
Neurology Cohort
Upadacitinib shows 94.1% remission at 26 weeks in Crohn's disease cohort Study compares upadacitinib and other therapies for Crohn's disease remission
This retrospective cohort study of 218 individuals with Crohn's disease found a 94.1% clinical remission rate at 26 weeks for upadacitinib, …
Upadacitinib showed a 94.1% remission rate for Crohn's disease patients at 26 weeks, but this finding comes from a very small group of just …
Obesity associated with reduced SLE relapse rates in Japanese registry cohort
Neurology Cohort
Obesity associated with reduced SLE relapse rates in Japanese registry cohort A Surprising Link Between Weight and Lupus Flares
This observational cohort study of 1134 patients with systemic lupus erythematosus in Japan found that obesity (BMI ≥25 kg/m2) was associate…
Being overweight or mildly obese might lower the risk of lupus relapses, challenging common beliefs about weight and autoimmune disease.
Meta-analysis links chronic kidney disease to higher mortality after intracerebral hemorrhage
Neurology Meta-analysis
Meta-analysis links chronic kidney disease to higher mortality after intracerebral hemorrhage Kidney Disease Linked to Higher Stroke Death Risk
This meta-analysis of 5,000 patients with spontaneous intracerebral hemorrhage found that chronic kidney disease was associated with higher …
Kidney disease makes surviving a brain bleed much harder, raising the risk of death and disability for patients with this common condition.
Masitinib 4.5 mg/kg/day associated with survival in ALS post-hoc analysis
Neurology RCT
Masitinib 4.5 mg/kg/day associated with survival in ALS post-hoc analysis This Drug Could Add Nearly Two Years to ALS Life
This post-hoc analysis of a randomized, double-blind, placebo-controlled trial in 130 ALS patients found that masitinib 4.5 mg/kg/day was as…
A new look at data suggests a specific drug might significantly extend life for some people with ALS.
Intermittent theta-burst stimulation of right putamen improves motor scores in Parkinson's disease patients
Neurology RCT
Intermittent theta-burst stimulation of right putamen improves motor scores in Parkinson's disease patients New Non-Invasive Method Eases Parkinsons Motor Symptoms Without Surgery
This randomized controlled trial in 19 Parkinson's disease patients found that intermittent theta-burst transcranial temporal interference s…
A new non-surgical brain treatment showed promise in reducing movement problems for Parkinsons patients.